5 clinically reviewed articles, written and peer-reviewed by the HealthRX.com Medical Team.
Showing 5 of 5 clinical reviews.
A clinician-grade guide to recognizing and managing an alirocumab efficacy plateau, including FDA-approved dose escalation from 75 mg to 150 mg every two weeks, real-world titration data, and decision frameworks for LDL-C non-responders.
A clinical deep-dive into alirocumab (Praluent) dose titration from 75 mg to 150 mg, when to escalate, what trial data show at maximum dose, and how real-world practice aligns with FDA labeling.
A complete clinical guide to re-starting Praluent (alirocumab) after a treatment gap, including FDA-approved dose escalation steps, titration timelines, and real-world evidence on LDL-C recovery after discontinuation.
A clinical guide to slow titration of Praluent (alirocumab), covering the FDA-approved 75 mg starting dose, step-up to 150 mg, real-world evidence, and strategies for patients with injection-site or LDL-response sensitivity.
A complete guide to the Praluent (alirocumab) standard titration schedule, including starting doses, escalation timing, LDL-C targets, and dose-adjustment criteria backed by FDA labeling and ODYSSEY trial data.